Introduction {#s1}
============

Bipolar disorder (BD) affects around 0.6% of the population and is associated with clinical comorbidities and increased standardized mortality ratios ([@CIT0027]; [@CIT0025]). Particularly, progression of BD has been associated with several unfavorable clinical outcomes, including reduced interepisode intervals, functional impairments and inferior responsiveness to treatment in late-stage BD patients when compared with early-stage ones ([@CIT0020]; [@CIT0500]; [@CIT0501]). In addition, evidence suggests that patients with BD present reduced resilience to stress and an increased vulnerability to new mood episodes as the illness progresses ([@CIT0013]). In fact, stress resilience and coping mechanisms are primarily mediated by the HPA axis, which appears to be dysfunctional in patients with BD ([@CIT0010]). BD patients have been shown to have a hyperactive HPA axis, in some cases with high levels of cortisol ([@CIT0007]) and non-suppression of its levels in the dexamethasone suppression test or the dexamethasone/cortisol releasing hormone test ([@CIT0038]). In addition, high-risk subjects, such as first-degree relatives, have also been shown to present elevated baseline cortisol levels ([@CIT0012]; [@CIT0022]) and abnormal responses to the dexamethasone/cortisol releasing hormone test ([@CIT0016]; [@CIT0026]). In this sense, HPA axis abnormalities seem to be a trait conferring vulnerability to mood disorders ([@CIT0011]).

One of the main players in HPA axis modulation is the glucocorticoid receptor (GR), which translocates from the cytosol to the nucleus upon hormone binding and acts as a transcription factor. The function of GR depends on a large molecular complex entailing several chaperones and co-chaperones, including FK506-binding protein 51 (FKBP51; [@CIT0003]). *In vitro* overexpression of human FKBP51 reduces hormone binding affinity and nuclear translocation of GR ([@CIT0041]), and high levels of FKBP51 have been shown to lead to GR insensitivity, accompanied by increased blood cortisol levels in New World monkeys ([@CIT0034]). Interestingly, glucocorticoids can induce the expression of FKBP51 as part of an intracellular ultra-short negative feedback loop for GR activity ([@CIT0035]).

Given the reported familial and genetic component of the pathophysiology of BD ([@CIT0040]), it is likely that most of these stress-related features reflect a particular genetic background. In this vein, several studies have suggested that the genetic contribution to BD operates mostly through gene-environment interactions ([@CIT0029]; [@CIT0023]). Mechanistically, environmental impact reprograms gene activity by changing epigenetic modifications, thus increasing the risk for the disease in susceptible subjects and interfering with the course of illness. Among such epigenetic modifications, alterations in DNA methylation have been consistently reported in patients with BD ([@CIT0009]; [@CIT0018]). Of note, chronic exposure to glucocorticoids has been shown to induce alterations in DNA methylation at the murine *FKBP5* gene and at the human *Fkbp5* gene in patients with post-traumatic stress disorder ([@CIT0042]; [@CIT0005]). Therefore, *FKBP5* methylation may be one of the mechanisms by which stress plays its role in BD pathophysiology.

Stress resilience and coping mechanisms are believed to be key elements in the development and progressive course of BD. However, the mechanisms behind the associated HPA axis dysfunction are still poorly understood, as is the role they play in determining the risk for the disease in susceptible subjects. Therefore, this study aimed to examine HPA axis activity and underlying molecular mechanisms in patients with BD, first-degree relatives, and healthy controls, with a focus on identifying clinical and epigenetic mechanisms associated with the development and progression of BD.

Methods {#s2}
=======

Subjects {#s3}
--------

The present study was approved by the Research Ethics Committee of Hospital de Clínicas de Porto Alegre (HCPA), Brazil, under protocol no. 12--0102. Subjects received a detailed description of the study, and gave written informed consent. All participants were at least 18 years old.

Twenty-four euthymic patients diagnosed with BD type I according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) Axis I criteria were recruited at an outpatient program of HCPA. Euthymia was confirmed using the Hamilton Depression Rating Scale (HDRS) and the Young Mania Rating Scale (YMRS; scores \< 7 for each scale). In order to evaluate whether the mechanisms under investigation were also involved in BD progression, we divided the BD patients into early (stages I and II) and late (stages III and IV) stages of the illness, according to a previously published staging model of BD ([@CIT0006]). For this purpose, a series of clinical parameters were collected using a semi-structured interview, including data on course of illness, functioning, and comorbidities, as previously described ([@CIT0030]; [@CIT0501]).

Eighteen siblings of patients with BD were also included in the study: each had at least one sibling with the diagnosis of BD type I. Siblings recruited for this study were not necessarily related to the 24 BD patients enrolled; therefore, both groups were considered independent in the analyses. Moreover, 26 nonrelated healthy controls without any history of psychiatric illnesses or neurological disorders were also recruited. Subjects were matched by frequency, so that age and sex would not differ between groups by the end of recruitment. Control subjects were selected at the Blood Bank at HCPA after screening for exclusion criteria. All of the participants were volunteers, with no specific compensation provided.

The exclusion criteria for BD patients, siblings, and controls were history of autoimmune diseases, chronic infection/inflammatory disorders, or any severe systemic disease, and use of immunosuppressive therapy. All subjects were clinically interviewed by a trained psychiatrist and evaluated using the Functioning Assessment Short Test (FAST; [@CIT0032]; [@CIT0006]) and the Childhood Trauma Questionnaire (CTQ; [@CIT0002]; [@CIT0015]) for the assessment of functioning and early childhood adverse events, respectively. Twenty milliliters of peripheral venous blood were collected from each subject for further analysis. All blood collections were performed at the same period of the day (late afternoon).

Dexamethasone Suppression Test {#s4}
------------------------------

All subjects underwent a low-dose dexamethasone suppression test with 1.0mg dexamethasone for the assessment of HPA axis activity. All subjects were informed that no foods or drinks should be taken for at least 30min prior to saliva collection. The first saliva sample was collected at 08:00 hours on the first day (T1). A second saliva sample was collected on the same day, at 23:00 hours (T2), followed by the oral administration of dexamethasone. On the next day, a third saliva sample was collected, around 08:00 hours, immediately after waking up (T3), and the last sample was collected at 16:00 hours (T4). All samples were kept at 4°C until arrival in the laboratory, where they were centrifuged, aliquoted, and stored at -20°C until further analysis.

Cortisol and Adrenocorticotropic Hormone {#s5}
----------------------------------------

Salivary cortisol levels were measured using the Cortisol Enzyme Immunoassay kit (Arbor Assay), according to the manufacturer's instructions. A standard curve ranging from 3200 to 0 pg/ml was used to calculate cortisol levels for each sample. Plasma samples were used for the measurement of adrenocorticotripic hormone (ACTH) levels using an ELISA kit (Calbiotech), according to the manufacturer's instructions. A standard curve ranging from 0 to 517 pg/ml was used to determine ACTH levels in the samples.

*Ex Vivo* GR Responsiveness {#s6}
---------------------------

Measurement of dexamethasone-induced *FKBP5* mRNA expression in peripheral blood mononuclear cells (PBMCs) was used to estimate GR responsiveness, as previously described ([@CIT0035], [@CIT0036]; [@CIT0008]). PBMCs were isolated from total heparinized blood by Ficoll-Hypaque density-gradient centrifugation (GE Healthcare). Following counting, cells were resuspended to a concentration of 0.5 x 10^6^ cells/ml in RPMI 1640 medium supplemented with 10% charcoal-treated fetal bovine serum, 10 µg/ml gentamycin, and 0.25 µg/ml amphotericin B. PBMCs were then seeded onto a 24-well plate in 0.5ml aliquots (0.25 x 10^6^ cells/well). Following overnight stabilization in culture, cells were treated for 24 hours with 10^--9^, 10^--8^, or 10^--7^ M dexamethasone or vehicle. Total RNA was isolated using the Illustra RNAspin Mini RNA Isolation kit (GE Healthcare) and reverse transcribed using the Omniscript Reverse Transcriptase kit (Qiagen), according to the manufacturers' instructions. The newly synthesized complementary DNA (cDNA) was then amplified by real-time polymerase chain reaction (PCR) performed on the LightCycler system (Roche Applied Science), using the QuantiFast SYBR Green PCR kit (Qiagen). The following primers were used: 5'-ccattgctttattggcctct-3' (forward) and 5'-ggatatacgccaacatgttcaa-3' (reverse) for *FKBP5* ([@CIT0024]); and 5'-agatgagtatgcctgccgtg-3' (forward) and 5'-tgcggcatcttcaaacctcc-3' (reverse) for beta-2 microglobulin.

Western Blot Analysis {#s7}
---------------------

For protein analysis, isolated PBMCs were lysed in 50 µL of lysis buffer (60mM Tris-HCl \[pH 6.8\], 2% SDS, and 10% saccharose), supplemented with 1:100 protease (Sigma) and phosphatase (Roche Applied Science) inhibitors, followed by sonication and determination of protein concentration using a BCA kit (Thermo Fisher Scientific). For immunoblot detection, 15 µg of cell lysate total protein were separated using sodium dodecyl sulfate polyacrylamide gel electrophoresis under denaturing conditions, followed by transfer onto nitrocellulose membranes. After blocking, membranes were incubated overnight with a monoclonal antibody against FKBP51 (1:1000, Bethyl), followed by a horseradish peroxidase-conjugated antibody against rabbit IgG (Cell Signaling). Signals were visualized using ECL detection reagent (Millipore) and monitored using the ChemiDoc MP Imaging System (BioRad). Band intensities were normalized by the intensity of a reference sample (pooled PBMCs) loaded onto each gel to ensure accurate comparison of samples loaded on different gels.

*FKBP5* DNA Methylation {#s8}
-----------------------

*FKBP5* methylation was analyzed by bisulfite pyrosequencing, as previously described ([@CIT0005]; [@CIT0005]). Genomic DNA was isolated from total blood using the Illustra blood genomicPrep Mini Spin kit (GE Healthcare), followed by spectrophotometric quantification (NanoDrop, Thermo Fisher). Approximately 300ng of DNA were converted with bisulfite using the EZ DNA Methylation kit (Zymo Research). Bisulfite-converted DNA samples were used as templates in PCR reactions for the amplification of intron 2, intron 7, and the putative promoter region of the *FKBP5* gene ([@CIT0005]). All sites analyzed were located close to glucocorticoid response elements (GREs).

Statistical Analysis {#s9}
--------------------

Statistical analyses were performed using PASW Statistics version 18.0. Descriptive statistics were used to report demographic and clinical characteristics of the sample. Normality of data distribution was assessed with Shapiro-Wilk's test and histogram visualization. Categorical variables were compared using chi-square or Fisher's exact tests. One-way analysis of variance (ANOVA), followed by Tukey's post hoc test, were performed to compare parametric variables between BD patients, siblings, and controls, and independent *t*-tests were performed to analyze differences in clinical and demographic data between early- and late-stage BD patients. Analyses of covariance were conducted, adjusting for the potential confounding variables of age, sex, body mass index (BMI), and years of education. The Kruskal-Wallis test was followed by the Mann-Whitney test; they were used to compare non-parametric variables between independent samples. Bonferroni correction was applied to control for multiple comparisons. Correlations between continuous variables were assessed using Pearson's or Spearman's correlation tests. Significance was set at *p* \< 0.05, except when otherwise specified.

Results {#s10}
=======

Sample {#s11}
------

Characteristics of BD patients, siblings, and healthy controls are shown in [Table 1](#T1){ref-type="table"}. Groups did not differ with regard to age, gender, BMI, smoking, years of education, or CTQ scores. Even though all participants were euthymic at enrollment, BD patients and siblings scored higher in mania and depression scales when compared to controls (YMRS: *F*(2.65) = 4.9, *p* = 0.01; HDRS: *F*(2.65) = 17.9, *p* \< 0.001). Moreover, BD patients presented higher FAST scores when compared with siblings and controls \[*F*(2) = 22.24, *p* \< 0.001\], whereas no significant differences in FAST scores were found between siblings and controls (*p* = 0.138). BD patients also presented a higher prevalence of hypothyroidism (χ^2^ = 15.6, *p* \< 0.001). Patterns of medication use in the BD patients recruited for this study were very similar to those previously described for international and Brazilian standards, as assessed by a multi-national, multi-center, observational cohort study ([@CIT0037]).

###### 

Characteristics of controls, siblings, and patients with bipolar disorder

  **Characteristic**                  **Controls (n = 26)**   **Siblings (n = 18)**   **Patients (n = 24)**   ***p***
  ----------------------------------- ----------------------- ----------------------- ----------------------- --------------
  Age (years)^a,d^                    46.9 (7.08)             51.1 (13.2)             46.9 (7.08)             0.453
  Gender (male/female)^c^             8/18                    6/12                    7/17                    0.959
  HDRS^a,d^                           0.65 (1.3)              3.56 (3.11)             4.17 (2.14)             **\<0.001**
  YMRS^a,d^                           0.08 (0.27)             1.06 (1.3)              0.96 (1.6)              **0.01**
  Body mass index^a,d^                28.1 (4.7)              27.3 (5.8)              30.3 (6.12)             0.183
  Smoking^c^                          33.3%                   7.7%                    25%                     0.094
  Years of education^a,d^             11.54 (3.95)            10.33 (4.34)            11.13 (3.6)             0.611
  FAST score^a,d^                     5.92 (6.37)             11.93 (12.3)            23.7 (9.92)             **\<0.001**
  CTQ score^a,d^                      33.04 (9.7)             35.12 (7.9)             39.04 (11.0)            0.131
  Age at illness onset^a^                                                             25.67 (10.7)            
  Length of euthymia (months)^b^                                                      11 (35.3)               
  Length of illness (years)^a^                                                        21.04 (10.8)            
  Number of manic/mixed episodes^a^                                                   5.3 (5.8)               
  Number of depressive episodes^a^                                                    8.5 (8.4)               
  Total number of episodes^a^                                                         13.8 (11.5)             
  Number of hospitalizations^a^                                                       5.38 (8.7)              
  **Comorbidities**                                                                                           
   Hypothyroidism^c^                  0%                      11.1%                   41.6%                   **\< 0.001**
   Hypertension^c^                    0%                      16.6%                   25%                     0.03
   Diabetes mellitus^c^               0%                      0%                      16.6%                   0.02
   Dyslipidemia^c^                    3.8%                    33.3%                   20.8%                   0.036
   Obesity^c^                         0%                      0%                      4.17%                   0.394
   Other^c^                           7.7%                    27.7%                   33.3%                   0.073
  **Medications**                                                                                             
   Mood stabilizers                                                                   66.6%                   
   Lithium                                                                            37.5%                   
   Valproate                                                                          25%                     
   Carbamazepine                                                                      8.3%                    
   Lamotrigine                                                                        4.2%                    
   Antidepressants                                                                    4.16%                   
   Atypical antipsychotics                                                            33.3%                   
   Typical antipsychotics                                                             12.5%                   
   Benzodiazepines                                                                    8.33%                   

^a^Mean (standard deviation); ^b^Median (interquartile range); ^c^Chi-square test; ^d^One-way ANOVA.

Cortisol and HPA Axis Activity {#s12}
------------------------------

Results of the dexamethasone suppression test are shown in [Table 2](#T2){ref-type="table"}. All groups presented significantly lower post-dexamethasone salivary cortisol levels compared to basal levels (T1 vs. T3; *p* \< 0.05 for all groups). Moreover, the cortisol suppression ratio did not differ between the groups. Basal salivary cortisol levels (T1) were similar in all groups, as were bedtime cortisol levels (T2). However, patients with BD presented higher post-dexamethasone cortisol levels (T3) when compared with controls \[*F*(2) = 4.21, *p* = 0.015; [Figure 1A](#F1){ref-type="fig"}\]. The findings remained similar when age, sex, BMI, and education were included as covariates. A positive correlation was also found between post-dexamethasone cortisol levels and total number of episodes in BD patients (*r* = -0.329, *p* = 0.017), and no significant correlation between FAST scores and post-dexamethasone cortisol levels was found (*r* = 0.156, p = 0.284), neither when considering the entire sample, nor when analyzing each group individually. No differences were found for the last time point (T4). The mean decline of cortisol levels throughout the day (diurnal slope) did not differ between the groups, nor did plasma ACTH levels.

###### 

Cortisol and HPA axis parameters

  **Characteristic**                  **Controls (n = 26)**   **Siblings (n = 18)**   **Patients (n = 24)**   ***p***
  ----------------------------------- ----------------------- ----------------------- ----------------------- ----------
  Cortisol (pg/µl)                                                                                            
   T1, basal levels^a^                2.84 (2.16)             3.13 (2.24)             3.1 (1.62)              0.881
   T2, bedtime levels^a^              1.16 (0.66)             0.98 (0.73)             1.89 (1.94)             0.102
   T3, post-dexamethasone levels^a^   0.23 (0.11)             0.32 (0.22)             0.41 (0.21)             **0.02**
   T4^a^                              0.26 (0.08)             0.38 (0.08)             0.37 (0.2)              0.087
  Cortisol suppression ratio^a,b^     13.47 (11.13)           11.55 (8.86)            9.64 (6.96)             0.462
  Diurnal slope, mean decline^a,c^    0.15 (0.13)             0.22 (0.13)             0.13 (0.08)             0.163
  Plasma ACTH levels (pg/ml)^a^       18.99 (11.57)           15.8 (7.25)             20.32 (12.2)            0.469

^a^Mean (standard deviation); ^b^Suppression ratio = cortisol T1 / cortisol T3; ^c^Diurnal slope = (cortisol T1 -- cortisol T2) / (time T2 -- awakening time). T1 = 08:00 hours on day 1; T2 = 23:00 hours on day 2 (pre-dexamethasone); T3 = 08:00 hours on day 2; T4 = 16:00 hours on day 2.

![HPA axis activity and FKBP51 alterations in bipolar disorder. (A) Post-dexamethasone salivary cortisol levels; one-way ANOVA followed by Tukey's post hoc test. (B) *Ex vivo* GR responsiveness assay. Isolated peripheral blood mononuclear cells were incubated with increasing concentrations of dexamethasone, with assessment of *FKBP5* mRNA levels after 24 hours; Kruskall-Wallis followed by Mann-Whitney test and Bonferroni correction. (C) Basal *FKBP5* mRNA levels; one-way ANOVA followed by Tukey's post hoc test. (D) FKBP51 protein levels; Kruskall-Wallis followed by Mann-Whitney test and Bonferroni correction. (E--F) Methylation status of the *FKBP5* gene at two specific CpG dinucleotides; one-way ANOVA followed by Tukey's post hoc test. \**p* = 0.008 (BD patients vs. controls). RQ: relative quantification.](ijnppy_pyu043_f0001){#F1}

GR Responsiveness {#s13}
-----------------

BD patients showed significantly lower *FKBP5* mRNA levels in response to the lower concentration of dexamethasone when compared to the control group (*U* = 22, *Z* = -2.66, *p* = 0.008; [Figure 1B](#F1){ref-type="fig"}). No differences were found for the two other dexamethasone concentrations. Siblings were not statistically different from controls or BD patients. No significant correlations were found between GR responsiveness and salivary cortisol levels at any of the assessed time points, nor in relation to number of episodes, length of illness, or mood symptoms.

Baseline *FKBP5* mRNA Levels {#s14}
----------------------------

Vehicle-treated cells from the previous experiment were also analyzed for baseline *FKBP5* mRNA levels. After log-transformation of data, no differences were found in any of the comparisons (*p* \> 0.05; [Figure 1C](#F1){ref-type="fig"}). No significant correlations were found between baseline *FKBP5* mRNA levels and clinical parameters.

FKBP51 Protein Levels {#s15}
---------------------

Considering that FKBP51 is a negative regulator of GR, we assessed basal FKBP51 protein levels in the PBMCs isolated from all subjects. Patients with BD presented increased FKBP51 protein levels when compared to siblings (*U* = 62, *Z* = -2.505, *p* = 0.012); a trend was also observed in the comparison with controls (*U* = 113, *Z* = -1.959, *p* = 0.05, [Figure 1D](#F1){ref-type="fig"}). A significant correlation was found between FKBP51 and post-dexamethasone cortisol levels (Spearman's *ρ* = 0.313, *p* = 0.049). No correlations were found between FKBP51 protein levels and basal *FKBP5* mRNA levels, GR responsiveness, or clinical parameters.

*FKBP5* Methylation {#s16}
-------------------

Based on previous evidence of epigenetic mechanisms modulating the FKBP51 ultra-short feedback loop ([@CIT0005]), we assessed DNA methylation of the *FKBP5* gene at three different loci (intron 7, intron 2, and promoter) in all subjects. Differences were found at two CpG sites (dinucleotides composed of a cytosine next to a guanine in the same strand of the DNA) in intron 7 and one CpG in intron 2 of the *FKBP5* gene, but only the differences at CpG 6 of intron 7 and CpG 2 of intron 2 remained significant after post hoc tests ([Table 3](#T3){ref-type="table"}). BD patients showed an increased percentage of methylation at intron 7 when compared with siblings \[CpG 6, *F*(2,57) = 5.58; *p* = 0.007; [Figure 1E](#F1){ref-type="fig"}\], and a trend was also observed in the comparison with controls (*p* = 0.054). Patients with BD also showed increased methylation at CpG 2 of intron 2 when compared with controls \[*F*(2,53) = 3.7, *p* = 0.04; [Figure 1F](#F1){ref-type="fig"}\]. No other differences regarding individual CpG sites were found in our sample. Significant negative correlations were found between the number of previous manic episodes and methylation status at two CpG sites of intron 7 (CpG 1: *r* = -0.444, *p* = 0.034; CpG5: *r* = -0.426, *p* = 0.043).

###### 

*FKBP5* methylation in patients, siblings, and controls (%)

                   **Controls (n = 26)**   **Siblings (n = 18)**   **Patients (n = 24)**   ***p***
  ---------------- ----------------------- ----------------------- ----------------------- -----------
  **Intron 7**                                                                             
  P1_CpG1^a,c^     69.6 (3.6)              70.7 (5.7)              68.3 (3.9)              0.239
  P1_CpG2^a,c^     90.6 (3.4)              93.2 (3.8)              91.3 (4.1)              0.12
  P1_CpG3^b,d^     100 (3.4)               99.9 (2.7)              97.6 (4.6)              **0.041**
  P1_CpG4^b,d^     79.6 (6.2)              78.2 (3.7)              79.9 (4.6)              0.249
  P1_CpG5^a,c^     47.8 (4.2)              48.5 (2.3)              49.0 (2.9)              0.482
  P1_CpG6^a,c^     56.9 (4.3)              55.5 (3.7)              60.1 (5.1)              **0.006**
  **Intron 2**                                                                             
  P4_CpG1^a,c^     66.6 (2.4)              66.7 (3.05)             66.9 (1.9)              0.893
  P4_CpG2^a,c^     59.8 (2.1)              59.9 (2.05)             61.6 (2.6)              **0.031**
  P4_CpG3^a,c^     48.6 (1.9)              50.4 (2.8)              50.4 (3.0)              0.058
  P4_CpG4^a,c^     61.2 (1.9)              61.4 (1.8)              60.6 (1.3)              0.322
  **Promoter**                                                                             
  GRE3_CpG1^b,d^   94.8 (6.2)              94.7 (4.4)              94.4 (5.5)              0.235
  GRE3_CpG2^a,c^   47.1 (1.5)              46.9 (1.6)              46.8 (1.9)              0.801
  GRE3_CpG3^a,c^   100                     100                     100                     1.000
  GRE3_CpG4^a,c^   92.5 (3.5)              90.9 (2.8)              92.3 (3.5)              0.315
  GRE3_CpG5^a,c^   84.2 (1.6)              84.3 (2.2)              85.0 (2.1)              0.427
  GRE3_CpG6^a,c^   62.2 (1.9)              62.4 (1.7)              63.5 (1.7)              0.059

^a^Mean (standard deviation); ^b^Median (interquartile range); ^c^One-way ANOVA test; ^d^Kruskal-Wallis test.

As previously reported ([@CIT0005]), further analyses were performed after summarizing the percentage of the 16 CpG sites into seven bins, according to their spatial proximity to the consensus GRE sites. No differences were found between the groups for percentage of methylation in the seven bins. Results remained unaltered after controlling for potential confounders. No correlations were found between *FKBP5* methylation and CTQ or FAST scores.

Analyses According to Staging {#s17}
-----------------------------

In order to assess whether the mechanisms above are involved in BD progression, we divided BD patients into early and late stages of illness, and further analyzed our data comparing the two staging groups. Late-stage patients presented higher results than early-stage ones for total number of episodes \[*t*(14.7) = -4.27, *p* = 0.001\], number of manic/mixed episodes \[*t*(13.6) = -3.57, *p* = 0.003\], number of depressive episodes \[*t*(15.8) = -2.91, *p* = 0.01\], number of hospitalizations \[*t*(13.3) = -2.73, *p* = 0.017\], and FAST scores \[*t*(21) = -3.32, *p* = 0.003\]; conversely, the two groups did not differ with regard to length of illness, age at illness onset, or any other sociodemographic or clinical variable ([Table 4](#T4){ref-type="table"}).

###### 

Characteristics of patients with early- vs. late-stage bipolar disorder

  **Characteristic**                    **Early-stage bipolar disorder (n = 10)**   **Late-stage bipolar disorder (n = 14)**   ***p***
  ------------------------------------- ------------------------------------------- ------------------------------------------ -----------
  Age (years)^a,c^                      44.4 (7.38)                                 48.79 (6.51)                               0.138
  Gender (male/female)^d^               3 / 7                                       4 / 10                                     0.993
  HDRS^a,c^                             3.4 (2.22)                                  4.71 (1.97)                                0.141
  YMRS^a,c^                             1.2 (1.93)                                  0.79 (1.13)                                0.544
  Body mass index^a,c^                  27.8 (4.95)                                 32.2 (6.3)                                 0.081
  Smoking^d^                            10%                                         35.7%                                      0.151
  Years of education^a,c^               12.4 (3.83)                                 10.21 (3.37)                               0.154
  Age at illness onset^a,c^             23.22 (10.87)                               26.07 (10.27)                              0.532
  Length of euthymia (months)^b,f^      10 (62.5)                                   12 (33.3)                                  0.815
  Length of illness (years)^a,c^        19.7 (12.59)                                22 (9.78)                                  0.619
  Number of manic/mixed episodes^a,c^   1.7 (0.82)                                  7.93 (6.45)                                **0.003**
  Number of depressive episodes^a,c^    3.9 (2.72)                                  11.79 (9.59)                               **0.01**
  Total number of episodes^a,c^         5.6 (2.63)                                  19.71 (11.95)                              **0.001**
  Number of hospitalizations^a,c^       0.9 (0.99)                                  8.57 (10.4)                                **0.017**
  FAST score^a,c^                       17.2 (8.16)                                 28.69 (8.27)                               **0.003**
  CTQ score^a,c^                        40.8 (11.9)                                 37.7 (10.6)                                0.516
  **Comorbidities**                                                                                                            
   Hypothyroidism^e^                    30%                                         50%                                        0.421
   Hypertension^e^                      10%                                         35.7%                                      0.341
   Diabetes mellitus^e^                 20%                                         14.3%                                      1.000
   Dyslipidemia^e^                      30%                                         21.4%                                      0.615
   Obesity^e^                           0%                                          7.14%                                      1.000
   Other^e^                             30%                                         28.6%                                      0.673
  **Medications**                                                                                                              
   Mood stabilizers^e^                  90%                                         50%                                        0.079
   Lithium^e^                           40%                                         35.7%                                      1.000
   Valproate^e^                         30%                                         21.4%                                      0.665
   Carbamazepine^e^                     20%                                         0%                                         0.163
   Lamotrigine^e^                       10%                                         0%                                         0.417
   Antidepressants^e^                   10%                                         0%                                         0.417
   Atypical antipsychotics^e^           30%                                         35.7%                                      1.000
   Typical antipsychotics^e^            0%                                          21.4%                                      0.239
   Benzodiazepines^e^                   10%                                         7.14%                                      1.000

^a^Mean (standard deviation); ^b^Median (interquartile range); ^c^Student *t*-test; ^d^Chi-square test; ^e^Fisher's exact test; ^f^Mann-Whitney test.

Late-stage BD patients showed increased post-dexamethasone cortisol levels when compared with controls \[*F*(3) = 2.96, *p* = 0.033; [Figure 2A](#F2){ref-type="fig"}\], differently from early-stage BD patients. Accordingly, late-stage patients presented reduced GR responsiveness to 10^-9^M dexamethasone when compared with controls (*U* = 6, *Z* = -2.603, *p* = 0.009; [Figure 2B](#F2){ref-type="fig"}); no difference was found between early-stage BD patients and controls (*U* = 16, *Z* = -1.854, *p* = 0.064), nor between early- and late-stage BD patients (*U* = 16, *Z* = -0.714, *p* = 0.475). The groups did not differ in terms of basal *FKBP5* mRNA or FKBP51 protein levels ([Figure 2C](#F2){ref-type="fig"} and [D](#F2){ref-type="fig"}). However, early-stage patients showed increased methylation at intron 7 when compared with BD siblings \[CpG 6, *F*(3.56) = 4.33; *p* = 0.008; [Figure 2E](#F2){ref-type="fig"}\] and controls (*p* = 0.046).

![HPA axis activity and FKBP51 alterations in patients with early- vs. late-stage bipolar disorder. (A) Post-dexamethasone salivary cortisol levels; one-way ANOVA followed by Tukey's post hoc test. (B) *Ex vivo* GR responsiveness assay; Kruskall-Wallis followed by Mann-Whitney test and Bonferroni correction. (C) Basal *FKBP5* mRNA levels; Kruskall-Wallis followed by Mann-Whitney test and Bonferroni correction. (D) FKBP51 protein levels; Kruskall-Wallis followed by Mann-Whitney test and Bonferroni correction. (E--F) Methylation status of the *FKBP5* gene at two specific CpG dinucleotides; one-way ANOVA followed by Tukey's post hoc test. BD: bipolar disorder.](ijnppy_pyu043_f0002){#F2}

Discussion {#s18}
==========

The present study showed that patients with BD, particularly at a late stage of illness, presented increased salivary post-dexamethasone cortisol levels when compared to controls. Consistent with these findings, BD patients presented reduced *ex vivo* GR responsiveness and increased basal protein levels of FKBP51. Moreover, patients presented increased intronic methylation at the *FKBP5* gene, which may be responsible for the reduced induction of *FKBP5* mRNA expression by GR. In addition, siblings of patients with BD presented significantly lower FKBP51 protein levels than BD patients, even though no differences were found in *FKBP5* basal mRNA levels. As far as we are aware, this is the first study to assess alterations in FKBP51 levels and epigenetic mechanisms in patients with BD and first-degree relatives. Taken together, our results provide evidence for a FKBP51-mediated and epigenetically-induced modulation of the stress axis in BD.

Increased post-dexamethasone cortisol levels reflect a diminished ability of dexamethasone to reduce cortisol levels overnight, possibly accounting for a dysfunctional HPA axis in patients with BD. This seems to be the case especially in late-stage BD patients, and the positive correlation found between post-dexamethasone cortisol levels and total number of episodes suggests that the dysfunction is related to the progression of BD. High post-dexamethasone cortisol levels had been previously associated with persistent deficits in executive performance in patients with mood disorders ([@CIT0039]), as well as with depression severity ([@CIT0028]). As also reported for patients with major depressive disorder (MDD) ([@CIT0004]), post-dexamethasone cortisol levels could be one of the mediators of increased recurrence of episodes in patients with late-stage BD: the number of previous mood episodes has already been shown to predict risk of recurrence in patients with BD ([@CIT0020]). In this scenario, our findings point to a prognostic value of dexamethasone suppression test results and HPA axis activity in BD.

BD patients, siblings, and controls did not show significant differences in ACTH levels. Therefore, we hypothesized that the HPA axis dysfunction seen in BD patients could be mostly due to the role of GR in the cortisol-induced negative feedback. Taking the *ex vivo* induction of *FKBP5* mRNA by dexamethasone as a measure of GR responsiveness, our results show that PBMCs from patients with BD---especially late-stage ones---induce significantly less *FKBP5* mRNA expression after dexamethasone stimulation when compared with controls. Among the mechanisms possibly implicated in this GR resistance, we found that patients with BD showed increased basal FKBP51 protein levels. In fact, we found a positive correlation between basal FKBP51 protein expression and post-dexamethasone cortisol levels. Increased FKBP51 protein levels have also been associated with increased recurrence of depressive episodes in patients with MDD ([@CIT0004]), which corroborates the current evidence of their role in increased recurrence of mood episodes and BD progression. Interestingly, these differences were not found in mRNA levels, suggesting that the increased protein levels found in BD patients were independent of mRNA expression levels. A discrepancy between mRNA and protein levels had been previously reported for a sample of patients with MDD ([@CIT0004]), possibly explained by an enhanced protein translation or stability in patients.

Taking into account the methylation status of *FKBP5*, patients with BD presented increased methylation levels when compared to controls and siblings, especially in distal intronic GREs (introns 2 and 7). Distal intronic elements are known to significantly contribute to the transcriptional regulation of *FKBP5* by glucocorticoids ([@CIT0017]); therefore, increased methylation in these regions may reduce the inducibility of *FKBP5* expression after dexamethasone stimulation. Of note, no correlation was found between DNA methylation and basal *FKBP5* mRNA and protein levels, suggesting that methylation at those regions may be important for GR-mediated *FKBP5* expression, but not for basal expression (for which transcription factors other than GR may be relevant). Interestingly, illness progression seems to correlate with reduced intronic methylation, based on negative correlations found between number of episodes and *FKBP5* methylation status, and the fact that methylation was increased only in early-stage BD patients. This result may be secondary to chronic stress and hypercortisolemia, based on the fact that GR activation can induce alterations in *Fkbp5* methylation, and chronic exposure to dexamethasone can lead to DNA demethylation in intronic CpGs in the *FKBP5* gene ([@CIT0005]).

Our results also suggest that some of the parameters analyzed regarding HPA axis activity and its modulation may be altered in siblings of patients with BD. Our post-dexamethasone cortisol results indicate that the HPA axis activity of BD siblings lies somewhere between that of controls and patients with BD, as also observed for GR responsiveness and FAST scores. Moreover, BD siblings presented significantly lower FKBP51 protein levels than BD patients, even though no differences were found in *FKBP5* basal mRNA levels. These results are consistent with the notion that non-affected siblings share biological underpinnings of BD, which could place them in a group of latent-stage BD ([@CIT0001]; [@CIT0006]). However, our sample consisted purely of adult BD siblings with an average age of 51.1±13.2, whereas the average age of illness onset for BD is estimated to be much lower, around 18 years old ([@CIT0031]). In fact, we believe siblings of BD patients may be considered a resilient group of individuals, because they have remained nonsymptomatic even though they may present specific BD endophenotypes. In this sense, only a longitudinal follow-up of siblings will adequately assess if they are more likely to develop BD due to the subtle alterations in functioning, HPA axis regulation, and FKBP51-related mechanisms.

Some limitations of our study need to be mentioned. Our relatively small sample size reduced the statistical power of secondary analyses; it would be interesting to see the effects of a larger sample on our results, especially in comparisons that came close to significance. In this sense, the small sample size precluded meaningful results in matched-pair analyses between related BD patient-siblings pairs. Moreover, even though the groups did not differ with regard to the use of medications, it is possible that different medications may have had an impact on the parameters analyzed (type I error). Conversely, the strengths of this study are the assessment of multiple cortisol parameters, which enabled us to discuss HPA axis activity from different points of view. Moreover, the inclusion of both BD patients and siblings in the analysis allowed us to discuss the role of environmental effects on the disorder. Improvements to the present study include a larger sample, the recruitment of acutely ill patients, assessment of neuropsychological data, analysis of *FKBP5* polymorphisms, and a longitudinal approach of the current analyses.

In summary, our findings draw attention to the role of HPA axis activity in the pathophysiology of BD from a novel perspective: namely, that of dysfunctional negative feedback of the HPA axis and impaired GR responsiveness due to increased FKBP51 levels and increased *FKBP5* intronic methylation. These results add substantial support to previous evidence of altered cortisol levels in mood disorders and may be crucial to improving our understanding of BD pathophysiology, development, and progression. A clearer understanding of the environmental and physiological stimuli leading to these alterations is essential to the development of effective strategies aiming at preventing the development of BD in high-risk subjects. Our data is also consistent with the notion that a set of biological markers have more pronounced changes in late-stage BD ([@CIT0014]; [@CIT0030]) and may help to explain the changes in resilience to stress as well as physical comorbidities found among these patients.
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